ABT-737 and ABT-263 are highly specific for BCL-2, BCL-xL, and BCL-w and have proven efficacy on BCL-2/BCL-xL-dependent tumors such as leukemia and lymphoma [99]. The gene discussed is BCL2L1; the disease is leukemia.